Volastra Therapeutics

Volastra Therapeutics

Biotechnology, 1361 Amsterdam Ave, New York, 10027, United States, 11-50 Employees

volastratx.com

  • twitter
  • LinkedIn

phone no Phone Number: 16*********

Who is VOLASTRA THERAPEUTICS

Volastra Therapeutics is a New York-based drug discovery and therapeutics company pioneering novel approaches to treating cancer by exploiting chromosomal instability (CIN), cancers most ...

Read More

map
  • 1361 Amsterdam Ave, New York, New York, 10027, United States Headquarters: 1361 Amsterdam Ave, New York, New York, 10027, United States
  • 2019 Date Founded: 2019
  • 11-50 Employees: 11-50
  • dollar-icon Revenue: $5 Million to $10 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 2836 | NAICS Code: 541714 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from VOLASTRA THERAPEUTICS

Volastra Therapeutics Org Chart and Mapping

Employees

Song Chen

Tumor Immunology Scientist I

Derek Cogan

Vice President, Chemistry

Michael Su

Chief Scientific Officer

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Volastra Therapeutics

Answer: Volastra Therapeutics's headquarters are located at 1361 Amsterdam Ave, New York, 10027, United States

Answer: Volastra Therapeutics's phone number is 16*********

Answer: Volastra Therapeutics's official website is https://volastratx.com

Answer: Volastra Therapeutics's revenue is $5 Million to $10 Million

Answer: Volastra Therapeutics's SIC: 2836

Answer: Volastra Therapeutics's NAICS: 541714

Answer: Volastra Therapeutics has 11-50 employees

Answer: Volastra Therapeutics is in Biotechnology

Answer: Volastra Therapeutics contact info: Phone number: 16********* Website: https://volastratx.com

Answer: Volastra Therapeutics is a New York-based drug discovery and therapeutics company pioneering novel approaches to treating cancer by exploiting chromosomal instability (CIN), cancers most targetable vulnerability. Founded by Lewis Cantley, Ph.D., Olivier Elemento, Ph.D., and Samuel Bakhoum, M.D., Ph.D., Volastra is advancing a novel synthetic lethal and immune activating pipeline. Leading its portfolio, Volastra has two KIF18A inhibitors in Phase 1 clinical trials for cancers with high levels of chromosomal instability.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access